What Is TB-500? Thymosin Beta-4, Actin Binding, and Research Applications

TB-500 is a synthetic research peptide built around the active, actin-binding region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid regulatory protein found in nearly every cell type. Where full-length Tβ4 is a large endogenous peptide involved in actin dynamics, angiogenesis, and tissue remodeling, TB-500 condenses much of the interest into a short, acetylated fragment with the sequence Ac-LKKTETQ. This article is a laboratory-oriented overview of what TB-500 is, how it relates to thymosin beta-4, the mechanism by which it interacts with actin, and the preclinical research contexts in which it has been studied. As with everything we cover, the framing here is strictly preclinical and biochemical: TB-500 is sold and discussed for research use only, not for human consumption.

TB-500 and Thymosin Beta-4: The Relationship

Thymosin beta-4 is the most abundant member of the beta-thymosin family, a group of small peptides (~43 amino acids) that act as the major intracellular reservoir for monomeric actin. Tβ4 has been studied for decades as a regulator of the actin cytoskeleton and, more recently, for roles in cell migration, blood-vessel formation, and wound repair in animal and cell-culture models.

TB-500 is not identical to thymosin beta-4. It is a synthetic heptapeptide corresponding to residues 17–23 of the full Tβ4 sequence — the segment widely described in the literature as the actin-binding active site. In other words, TB-500 reproduces a functional core of the larger protein rather than the whole molecule. Notably, fragments containing this region have been detected in wound fluid, suggesting that short LKKTETQ-bearing peptides can arise naturally as breakdown products of Tβ4. Because the two are frequently conflated in vendor materials, researchers should treat "TB-500" and "thymosin beta-4" as related but distinct entities when interpreting study data.

The Active Ac-LKKTETQ Fragment

The defining feature of TB-500 is its sequence: Ac-LKKTETQ (leucine–lysine–lysine–threonine–glutamate–threonine–glutamine), with an N-terminal acetyl group. This seven-residue motif, designated 17LKKTETQ23 within the parent protein, has been identified across the biochemical literature as the principal actin-binding region of thymosin beta-4 and as a sequence associated with cell migration and wound-healing activity in experimental systems.

• Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ)
• Origin: residues 17–23 of the 43-amino-acid thymosin beta-4 protein
• Acetylation: the N-terminal acetyl cap is a common modification used to improve stability of synthetic peptides
• Designation: historically described as the 'actin-binding active site' of Tβ4

An important nuance: while LKKTETQ is the historically named actin-binding motif, crystallographic work indicates that essentially the entire length of thymosin beta-4 contributes to its actin interaction. This means a short fragment like TB-500 may not fully reproduce every property of the intact protein — a distinction that matters when comparing fragment studies to full-length Tβ4 studies.

Mechanism: G-Actin Sequestration and Cytoskeletal Dynamics

The best-characterized molecular function of thymosin beta-4 is G-actin sequestration. Actin exists in two forms: globular monomers (G-actin) and polymerized filaments (F-actin). Cells maintain a large pool of unpolymerized G-actin, and beta-thymosins are the proteins that hold this pool in reserve. Tβ4 binds monomeric (globular) actin in a roughly 1:1 complex, with reported dissociation constants generally in the range of about 0.4–1 µM depending on conditions and nucleotide state.

By binding G-actin, thymosin beta-4 prevents those monomers from nucleating or adding to the ends of growing filaments, and it also slows the exchange of the actin-bound nucleotide. Functionally, this makes Tβ4 a buffer that regulates how much actin is available for polymerization. When a cell needs to build filaments — for example during migration — proteins such as profilin can exchange with Tβ4 to release actin back into the polymerizable pool. This dynamic sequester-and-release cycle is central to cytoskeletal assembly and cell motility.

Angiogenesis and VEGF in Research Models

Beyond actin handling, thymosin beta-4 has been investigated in preclinical models for angiogenesis — the formation of new blood vessels. In cell-culture and animal studies, Tβ4 has been reported to promote endothelial cell migration and adhesion, tubule formation, and aortic-ring sprouting. Some studies report that Tβ4 can up-regulate vascular endothelial growth factor (VEGF) expression and that its pro-angiogenic effects involve signaling pathways such as Notch in endothelial cells.

Importantly, the literature is not fully settled on whether thymosin beta-4 is intrinsically angiogenic or whether part of its activity is mediated through VEGF and downstream pathways. Researchers have also specifically examined whether the actin-binding site contributes to angiogenic activity. These findings come from in vitro assays and rodent models (for example, mouse ischemic hindlimb and critical limb ischemia models) and should not be extrapolated to humans. They describe what has been observed in controlled experimental systems, not clinical outcomes.

Stem-Cell and Cell-Migration Effects

Because actin remodeling underlies how cells move, thymosin beta-4 and its fragments have been studied in the context of cell migration and, in some reports, the recruitment or supportive behavior of progenitor and stem cells. In endothelial systems, Tβ4 has been associated with an adhesive and proteolytic migratory phenotype. In combination studies, Tβ4 has been investigated alongside adipose-derived stem cells in mouse ischemic-limb models to examine effects on cell viability and tissue repair signaling.

The throughline across this work is mechanistic: a peptide that influences the availability of actin monomers can, in turn, influence the cytoskeletal rearrangements that cells use to migrate, adhere, and reorganize during tissue remodeling. For researchers, this is what makes the LKKTETQ fragment an interesting probe. None of this constitutes evidence of a therapeutic effect in people; it is a description of biological activity observed in laboratory models.

How TB-500 Differs From BPC-157

TB-500 is frequently discussed alongside BPC-157, another widely studied research peptide, and the two appear together in our Wolverine Blend. Despite often being grouped, they are mechanistically distinct:

• Origin: TB-500 derives from thymosin beta-4 (the LKKTETQ actin-binding fragment). BPC-157 is a synthetic peptide based on a partial sequence of a protein found in gastric juice.
• Primary mechanism studied: TB-500 research centers on G-actin sequestration and actin-cytoskeleton dynamics. BPC-157 research has focused on angiogenic and cytoprotective signaling, including nitric oxide and growth-factor pathways, in animal models.
• Sequence length: TB-500 is a short heptapeptide (Ac-LKKTETQ); BPC-157 is a 15-amino-acid peptide.
• Why they are blended in research: the two are paired in the Wolverine Blend because their distinct mechanisms are sometimes studied together in tissue-repair contexts.

For a deeper look at the second half of that pairing, see our companion overview, What is BPC-157? A Research Overview.

Reconstitution and Lab Handling

TB-500 is typically supplied as a lyophilized (freeze-dried) powder. In a laboratory setting, lyophilized peptides are generally reconstituted with bacteriostatic or sterile water and kept cold. General handling principles that apply to research peptides include:

• Store the lyophilized powder cold and protected from light and moisture until use.
• Reconstitute gently — direct the solvent against the vial wall rather than forcefully onto the powder, and swirl rather than shake.
• Once in solution, peptides are usually kept refrigerated and used within a limited window; avoid repeated freeze-thaw cycles.
• Confirm identity, purity, and lot before use by reviewing the product's third-party Certificate of Analysis.

The specific concentrations and volumes used in any experiment depend entirely on the protocol and are determined by the researcher — we do not provide human dosing or administration instructions. Because purity directly affects experimental reproducibility, we recommend reading How to Read a Certificate of Analysis and our overview of Purity Standards in Research Peptides. Every lot we ship is HPLC-tested and lot-tracked; you can confirm documentation on our verification page.

Research Use Only

TB-500 is not approved by the FDA for any human use and is not intended for human consumption. The studies summarized here were conducted in cell-culture systems and animal models; they describe observed biological activity, not clinical efficacy or safety in people. Nothing in this article should be read as a dosing protocol, a medical claim, or guidance for administration to humans. TB-500 and all compounds we offer are intended solely for in vitro and laboratory research by qualified professionals.

To explore TB-500, the Wolverine Blend, and our other lot-tracked, third-party-tested research compounds, browse the full product catalog.